Rein Therapeutics, Inc. Earnings Per Share Disclosure
13. Net Loss per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
|
|
Year Ended December 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Numerator: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(62,883 |
) |
|
$ |
(15,732 |
) |
Denominator: |
|
|
|
|
|
|
||
Weighted average common shares outstanding—basic and diluted |
|
|
17,938,899 |
|
|
|
4,598,715 |
|
Net loss per share attributable to common stockholders—basic and diluted |
|
$ |
(3.51 |
) |
|
$ |
(3.42 |
) |
The Company’s potential dilutive securities, which include stock options as of December 31, 2024 and 2023, have been excluded from the computation of diluted net loss per share attributable to common stockholders whenever the effect of including them would be to reduce the net loss per share. In periods where there is a net loss, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
|
|
Year Ended December 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Options to purchase common stock |
|
|
3,169,468 |
|
|
|
2,212,102 |
|
Warrants to issue shares of common stock |
|
|
7,353,442 |
|
|
|
3,726,696 |
|
Series X Preferred Stock issued and outstanding, as converted |
|
|
12,232,000 |
|
|
|
24,610,000 |
|
Total |
|
|
22,754,910 |
|
|
|
30,548,798 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Apr 7, 2025 | Showing above |
| 2023 | Apr 15, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.